# Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Source: https://onco.cc/trials/nct06004661/  
OnCo record `nct06004661` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function is a phase 2 interventional study registered as NCT06004661 by Novartis Pharmaceuticals, with 23 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-12-14. Interventions recorded: AAA617, 68Ga-PSMA-11. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06004661
- Phase: 2
- Setting: An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT06004661: https://clinicaltrials.gov/study/NCT06004661

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct06004661.json